Octreotide LAR

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Acromegaly

Conditions

Acromegaly

Trial Timeline

Dec 1, 2002 → —

NCT ID

NCT00128232

About Octreotide LAR

Octreotide LAR is a phase 3 stage product being developed by Novartis for Acromegaly. The current trial status is completed. This product is registered under clinical trial identifier NCT00128232. Target conditions include Acromegaly.

What happened to similar drugs?

13 of 20 similar drugs in Acromegaly were approved

Approved (13) Terminated (1) Active (7)

🔄Pasireotide LARNovartisPhase 3

🔄Octreotide acetate 30 mg suspensionNovartisPhase 3

✅Sandostatin LAR + pegvisomant + cabergolineNovartisApproved

✅Octreotide acetate and cabergoline/Octrotide and SomavertNovartisApproved

✅Sandostatin LARNovartisApproved

🔄Pasireotide + OctreotideNovartisPhase 3

✅Sandostatin (Octreotide Acetate)NovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06784752	Phase 3	Recruiting	May 30, 2025	Jan 5, 2034	Somatostatin Receptor Positive (SSTR+)
NCT01886287	Phase 2	Terminated	Dec 1, 2013	Oct 1, 2014	Neuroendocrine Carcinoma
NCT00166725	Phase 2	Completed	Feb 1, 2004	—	Prostate Cancer
NCT00128232	Phase 3	Completed	Dec 1, 2002	—	Acromegaly
NCT00225979	Phase 3	Completed	Nov 1, 2002	Mar 1, 2005	Acromegaly

Competing Products

20 competing products in Acromegaly

See all competitors

Product	Company	Stage	Hype Score
Alesse	Novartis	Phase 2	31
ONO-5788 + ONO-5788 Placebo + Octreotide	Ono Pharmaceutical	Phase 1	21
ONO-5788 + [14C]-ONO-5788	Ono Pharmaceutical	Phase 1	29
Pasireotide LAR	Novartis	Phase 3	40
Octreotide acetate 30 mg suspension	Novartis	Phase 3	40
Pasireotide long acting release formulation	Novartis	Pre-clinical	26
Sandostatin LAR + pegvisomant + cabergoline	Novartis	Approved	43
Octreotide acetate and cabergoline/Octrotide and Somavert	Novartis	Approved	43
Sandostatin LAR	Novartis	Approved	43
Pasireotide + Octreotide	Novartis	Phase 3	40
Sandostatin (Octreotide Acetate)	Novartis	Approved	39
Octreotide acetate	Novartis	Approved	35
octreotide FluidCrystal® injection depot	Novartis	Phase 2	35
Octreotide LAR	Novartis	Phase 3	40
Pasireotide	Novartis	Phase 2	35
Pasireotide LAR 60 mg + Pegvisomant	Novartis	Approved	39
Octreotide	Novartis	Approved	43
Octreotide LAR 30 MG Injection	Novartis	Approved	43
Pasireotide LAR	Novartis	Phase 2	35
Pasireotide (SOM230), Octreotide (Sandostatin)	Novartis	Phase 2	35